Regorafenib Phase 2 Trial for Metastatic Medullary Thyroid Cancer

Share this content:
Researchers are studying regorafenib, a multi kinase inhibitor, as treatment for metastatic medullary thyroid cancer.
Researchers are studying regorafenib, a multi kinase inhibitor, as treatment for metastatic medullary thyroid cancer.

Title: A Phase 2 Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer1

Principal Investigator: Jochen Lorch, MD, Dana-Farber Cancer Institute

Description: For this open label phase 2 study (ClinicalTrials.gov Identifier: NCT02657551), researchers are investigating the efficacy and safety of regorafenib, an orally-administered multi-kinase inhibitor, among patients with metastatic medullary thyroid cancer who received at least 1 prior therapy.

There is 1 trial arm: oral, daily predetermined regorafenib dosage for 3 weeks per cycle.

Primary outcomes are response and progression-free survival. Secondary outcomes are safety, radiographic response, and response-associated biomarkers.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02657551.

Status: This study is open and recruiting patients as of February 2, 2017.

Regorafenib is approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal cancer and advanced or unresectable gastrointestinal stromal tumors.

Reference

  1. Clinicaltrials.gov. A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer. NCT02657551. https://clinicaltrials.gov/ct2/show/NCT02657551 Accessed February 2, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters